-
公开(公告)号：EP3517541A1
公开(公告)日：2019-07-31
申请号：EP19156409.5
申请日：2013-05-06
Applicant: Nicox Ophthalmics, Inc.
Inventor： CAVANAGH, Thomas , BARMAN, Shikha P. , HAO, Tian , LELAND, Thomas B. , THEKKEDATH, Ritesh V.
Abstract: The present invention provided nanocrystals of fluticasone propionate having an X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2θ further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2θ, characterized in that :the nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates,wherein said nanoplates have an average size between 100 and 1000 nm.
-
公开(公告)号：EP3458468A1
公开(公告)日：2019-03-27
申请号：EP17725744.1
申请日：2017-05-18
Applicant: NZP UK Limited
Inventor： WEYMOUTH-WILSON, Alexander Charles , KOMSTA, Zofia , WALLIS, Laura , DAVIES, Ieuan , WANG, Jingjing
-
33.发明授权
公开(公告)号：EP2852285B1
公开(公告)日：2018-08-08
申请号：EP13784674.7
申请日：2013-04-29
Applicant: Neupharma, Inc.
Inventor： QIAN, Xiangping
IPC: C07J41/00 , C07J43/00 , C07J71/00 , A61K31/585 , A61P35/00
CPC classification number: C07J41/0011 , C07J19/00 , C07J41/0005 , C07J43/003 , C07J71/0021
Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
-
34.发明公开11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION 审中-公开11BETA-羟基类固醇用于与线粒体功能障碍有关的线粒体生物学和疾病
公开(公告)号：EP3309166A2
公开(公告)日：2018-04-18
申请号：EP17175566.3
申请日：2014-01-23
Applicant: Sphaera Pharma Pvt. Ltd.
Inventor： Dugar, Sundeep , Schreiner, Frederic George , Mahajan, Dinesh , Sharma, Amit , Patil, Ishwar Rakesh , Kuila, Bilash
IPC: C07J71/00 , C07J5/00 , C07J1/00 , C07J3/00 , C07J7/00 , C07J9/00 , C07J11/00 , C07J17/00 , C07J21/00 , C07J31/00 , C07J41/00 , C07J43/00 , A61K31/56 , A61P21/00
CPC classification number: C07J17/00 , C07J1/0011 , C07J1/0022 , C07J3/005 , C07J5/0015 , C07J5/0053 , C07J7/0005 , C07J7/002 , C07J7/007 , C07J9/00 , C07J11/00 , C07J21/00 , C07J21/006 , C07J31/006 , C07J41/0011 , C07J41/0016 , C07J41/0038 , C07J41/005 , C07J43/003
Abstract: The present invention provides novel compounds of 11β-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.
Abstract translation: 本发明提供了11β-羟基类固醇的新化合物及其组合物及其作为药物用于预防或逆转线粒体损伤，用于治疗或预防与线粒体功能障碍或耗竭有关的疾病，以及诱导线粒体再生或重建作为 治疗与人或动物受试者中线粒体结构和功能异常有关的疾病。 本文还公开了诊断线粒体损伤和诊断设计用于治疗，预防或逆转线粒体损伤或耗竭的治疗成功或失败的方法。
-
公开(公告)号：EP3131556A4
公开(公告)日：2017-10-25
申请号：EP15779875
申请日：2015-04-09
Applicant: SHANGHAI KE PHARMACEUTICAL CO LTD
Inventor： ZHU MIN-SHENG , SUN JIE , PAN YANG
IPC: A61K31/7048 , A61K31/7034 , A61P11/00 , A61P11/06 , A61P11/08 , C07J71/00
CPC classification number: A61K31/704 , A61K9/0073 , A61K31/7034 , A61K36/185 , C07J63/008 , C07J71/0005
Abstract: The present disclosure relates to treatment of a pulmonary disease. The methods and kits provided herein facilitate relieving the symptoms resulting from the pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease (COPD), etc.).
-
Patent Agency Ranking36.发明公开6-ALKYL-7-HYDROXY-4-EN-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS 有权作为中间体生产甾体FXR调节剂的6-烷基-7-羟基-4-烯-3-酮类甾体
公开(公告)号：EP3221331A1
公开(公告)日：2017-09-27
申请号：EP15800909.2
申请日：2015-11-19
Applicant: NZP UK LIMITED
Inventor： WEYMOUTH-WILSON, Alexander , KOMSTA, Zofia , BOYDELL, James , OTTER, Carl , WALLIS, Laura , BATCHELOR, Rhys
Abstract: The invention relates to compounds of formula (I), wherein R1, R2, Y, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.
Abstract translation: 本发明涉及式（I）的化合物，其中R 1，R 2，Y，R 4和R 5如本文所定义。 这些化合物是合成胆汁酸合成的中间体。
-
37.发明公开SALACIA COMPOSITIONS, METHODS OF TREATMENT BY THEIR ADMINISTRATION, AND METHODS OF THEIR PREPARATION 审中-公开SALACIA-ZUSAMMENSETZUNGEN，BEHANDLUNGSVERFAHREN MITTELS VERABREICHUNG DAVON UND VERFAHREN ZU DEREN HERSTELLUNG
公开(公告)号：EP3071214A4
公开(公告)日：2017-09-06
申请号：EP14864855
申请日：2014-11-19
Applicant: OMNIACTIVE HEALTH TECH (CANADA) LTD
Inventor： DESHPANDE JAYANT , GHANAM KHADIJA , EWART STEPHEN , JUTURU VIJAYA
IPC: A61K36/37 , A61K31/352 , A61K31/575 , A61P3/04 , C07H7/04 , C07J71/00 , C12N9/04 , C12N9/16
CPC classification number: A61K36/37 , A23L33/10 , A23L33/105 , A61K31/122 , A61K31/192 , A61K31/7048
Abstract: A Salacia composition described herein significantly reduces appetite, activates Hormone Sensitive Lipase, and manages a healthy lipid profile through inhibition of HMG-CoA Reductase enzyme. Salacia compositions described herein include of at least 12% of polyphenols, 2% of mangiferin and 1% of 25,26-oxidofriedelane-1,3-dione by weight of the composition in the form of extract. The composition is obtained by continuous solvent extraction, employing non-aqueous food grade solvents. Salacia compositions herein reduce appetite by about 18% of routine diet, when effective amounts are administered to a subject in need thereof. Effective management of a healthy lipid profile is thus possible with synergistic combination of reduction in energy intake, activation of Hormone Sensitive Lipase, and inhibition of HMG-CoA Reductase enzyme responsible for cholesterol metabolism.
Abstract translation: 本文所述的五层龙组合物显着降低食欲，激活激素敏感性脂肪酶，并通过抑制HMG-CoA还原酶来管理健康的脂质特征。 本文所述的沙拉西亚组合物包含按提取物形式的组合物的重量计至少12％的多酚，2％的芒果苷和1％的25,26-氧化十三烯-1,3-二酮。 该组合物通过使用非水性食品级溶剂的连续溶剂萃取而获得。 当将有效量给予有需要的受试者时，本文中的Salacia组合物减少约18％常规饮食的食欲。 因此，通过协同减少能量摄入，激活激素敏感性脂肪酶和抑制负责胆固醇代谢的HMG-CoA还原酶，可以有效管理健康的血脂谱。
-
公开(公告)号：EP3049089A4
公开(公告)日：2017-08-09
申请号：EP14849674
申请日：2014-09-25
Applicant: VAN ANDEL RES INST , SHANGHAI INST MATERIA MEDICA CAS
Inventor： XU HUAQIANG ERIC , HE YUANZHENG , MELCHER KARSTEN , YI WEI , SHI JINGJING
CPC classification number: C07J71/0047 , C07J3/005 , C07J5/0053
Abstract: The present invention relates to novel glucocorticoid compounds. The invention also relates to methods of using these compounds, the synthesis of these compounds, and to compositions and formulations comprising the glucocorticoid compounds, and uses thereof.
Abstract translation: 本发明涉及新的糖皮质激素化合物。 本发明还涉及使用这些化合物的方法，这些化合物的合成，以及包含该糖皮质激素化合物的组合物和制剂及其用途。
-
公开(公告)号：EP3186267A1
公开(公告)日：2017-07-05
申请号：EP15763482.5
申请日：2015-08-25
Inventor： KUDOVA, Eva , CHODOUNSKA, Hana , KAPRAS, Vojtech , VYKLICKY, Ladislav , VALES, Karel , JAHN, Ullrich
IPC: C07J1/00 , C07J9/00 , C07J13/00 , C07J31/00 , C07J41/00 , C07J43/00 , C07J63/00 , C07J71/00 , A61K31/56 , A61P25/00 , A61P25/08 , A61P25/28 , A61P25/24 , A61P25/22 , A61P25/18 , A61P25/30 , C07C279/14 , C07C305/20 , C07C211/63 , C07C13/60 , C07C55/00
CPC classification number: C07J43/003 , C07C59/80 , C07C305/20 , C07C2603/26 , C07D209/36 , C07D213/18 , C07D317/72 , C07J1/0007 , C07J1/0011 , C07J9/00 , C07J9/005 , C07J13/007 , C07J31/006 , C07J41/0005 , C07J41/0033 , C07J41/0038 , C07J53/001 , C07J63/008 , C07J71/0005
Abstract: The present invention provides amphiphilic compounds with a tetradecahydrophenanthrene skeleton of formula (I), wherein R1-R5 are as defined herein, and their enantiomers, exhibiting neuroprotective effects, for use as medicaments for treating neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain , addiction, multiple sclerosis, epilepsy, glioma, and a pharmaceutical composition containing said compound.
Abstract translation: 本发明提供了具有十四氢菲构架的两亲化合物及其对映异构体，表现出神经保护作用，其作为药物用于治疗与谷氨酸能神经递质系统失衡相关的神经精神病症，例如CNS的缺血性损伤，CNS的神经退行性改变和病症，情感障碍 ，抑郁症，创伤后应激障碍以及与压力，焦虑，精神分裂症和精神障碍有关的疾病，疼痛，成瘾，多发性硬化症，癫痫症，神经胶质瘤和含有所述化合物的药物组合物。
-
40.发明授权EXTRACTS AND COMPOUNDS FROM AGAPANTHUS AFRICANUS AND THEIR USE AS BIOLOGICAL PLANT PROTECTING AGENTS 有权提取物及其化合物从百子莲非洲种及其作为生物农药
公开(公告)号：EP1903876B1
公开(公告)日：2017-05-31
申请号：EP06754546.7
申请日：2006-06-24
Applicant: AgrarForum AG , AgrarForum SA (PTY) Ltd.
Inventor： PRETORIUS, Johannes Christiaan
-
-
-
-
-
-
-
-
-
Search Results
891
records
(took 0.026 seconds)
